These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 33546122)
1. Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers. Dok R; Glorieux M; Bamps M; Nuyts S Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546122 [TBL] [Abstract][Full Text] [Related]
2. ATR inhibition sensitizes HPV Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma. Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870 [TBL] [Abstract][Full Text] [Related]
4. The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma. Zhou C; Parsons JL Expert Rev Mol Med; 2020 Jul; 22():e3. PubMed ID: 32611474 [TBL] [Abstract][Full Text] [Related]
5. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation. Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407 [TBL] [Abstract][Full Text] [Related]
6. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma. Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066 [TBL] [Abstract][Full Text] [Related]
8. Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas. Dok R; Bamps M; Glorieux M; Zhao P; Sablina A; Nuyts S Int J Cancer; 2020 Feb; 146(4):1075-1085. PubMed ID: 31283004 [TBL] [Abstract][Full Text] [Related]
9. ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. Bright SJ; Manandhar M; Flint DB; Kolachina R; Ben Kacem M; Martinus DK; Turner BX; Qureshi I; McFadden CH; Marinello PC; Shaitelman SF; Sawakuchi GO JCI Insight; 2024 Oct; 9(19):. PubMed ID: 39235982 [TBL] [Abstract][Full Text] [Related]
10. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer. Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721 [TBL] [Abstract][Full Text] [Related]
11. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931 [TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113 [TBL] [Abstract][Full Text] [Related]
13. Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. Karukonda P; Odhiambo D; Mowery YM Mol Carcinog; 2022 Feb; 61(2):225-238. PubMed ID: 34964992 [TBL] [Abstract][Full Text] [Related]
14. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345 [TBL] [Abstract][Full Text] [Related]
15. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176 [TBL] [Abstract][Full Text] [Related]
16. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821 [TBL] [Abstract][Full Text] [Related]
17. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins. Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202 [TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma. Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606 [TBL] [Abstract][Full Text] [Related]
19. MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma. Berggren KL; Restrepo Cruz S; Hixon MD; Cowan AT; Keysar SB; Craig S; James J; Barry M; Ozbun MA; Jimeno A; McCance DJ; Beswick EJ; Gan GN Oncogene; 2019 Nov; 38(48):7329-7341. PubMed ID: 31417185 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]